查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1464803

動脈粥狀硬化藥物市場：依藥物類別、給藥途徑、階段及通路分類－2024年至2030年全球預測

Atherosclerosis Drugs Market by Drug Class (Anti-Hypertensive Drugs, Antiplatelet Agents, Cholesterol-lowering Drugs), Route of Administration (Injectable, Oral), Disease Stage, Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

動脈粥狀硬化藥物市場規模預計2023年為225.9億美元，2024年達238.2億美元，預計2030年將達332.3億美元，複合年成長率為5.66%。

動脈粥狀硬化藥物是指各種旨在減緩或逆轉動脈中斑塊形成（稱為動脈粥狀硬化）的藥物。這種積聚可能導致心臟病、中風和其他心血管問題。導致這些藥物擴大使用的關鍵因素包括全世界心血管疾病盛行率的上升、認知和診斷率的提高、藥物開發的進步以及患動脈粥樣硬化的風險增加，例如人口老齡化程度很高。 。然而，這些藥物並非沒有挑戰，包括潛在的副作用、個別特異性療效和高昂的治療成本，特別是對於較新的、受專利保護的藥物。為了解決這些問題，需要繼續努力開發更有效、更安全的藥物，實施降低醫療成本的策略，並改善患者對生活方式改變的教育，以補充藥物治療的研究。生物技術的進步和個人化醫療方法可提供針對個人遺傳體質的治療，預計將為改善動脈硬化藥物的開發帶來多樣化的機會。

主要市場統計
基準年[2023] 225.9億美元
預測年份 [2024] 238.2億美元
預測年份 [2030] 332.3億美元
複合年成長率（%） 5.66%

依藥物類別分類，降膽固醇藥物作為常見動脈粥狀硬化治療藥物的採用率較高

抗血小板劑是防止血液中的血小板聚集並形成血栓的藥物。血栓形成是動脈粥狀硬化中動脈狹窄的主要原因，這可能導致心臟病發作和中風。透過抑制血小板凝集，這些藥物可以降低此類事件的風險。抗高血壓藥是用來降低高血壓患者血壓的藥物。高血壓是動脈硬化及其併發症的重要危險因子。這些藥物透過多種機制降低血壓，減輕心血管系統的負擔。降膽固醇藥又稱為降血脂藥，主要是降低血液中的脂質（脂肪）水平，特別是降低動脈斑塊的主要成分低密度脂蛋白（LDL）膽固醇。透過降低低密度脂蛋白膽固醇，它可以抑制動脈硬化的進展並降低心血管事件的風險。

分銷管道 透過線上管道提高動脈粥狀硬化藥物的供應

醫院藥局是一個主要的通路，特別是對於臨床環境中動脈粥狀硬化的急性治療和管理。此管道確保接受住院治療的患者即時獲得必要的藥物，並促進快速開始治療。零售藥局是直接向大眾分發動脈粥狀硬化藥物的重要管道。零售藥局地理覆蓋範圍廣，為廣大患者群體（包括都市區和農村地區）提供方便的配藥服務。零售藥局允許患者透過實體店處方箋，並在院外管理慢性疾病（包括動脈粥狀硬化）方面發揮至關重要的作用。由於數位健康平台的進步，線上藥局已成為快速成長的分銷管道。網路藥局為患者提供線上訂購藥物並直接送貨上門的便利選擇。此管道對於行動不便或居住在偏遠地區的患者特別有利。

區域洞察

美洲在強大的研發基礎設施、龐大的醫療支出以及大型製藥企業的強大影響力的背景下，正在積極開發動脈硬化藥物。該地區受益於先進的醫療保健框架和促進藥物創新和快速採用的有利政府政策。另一方面，以中國、日本、印度為代表的亞太地區，動脈硬化治療藥物市場正在快速成長。這種快速成長的推動因素包括醫療保健意識的提高、心血管疾病盛行率的上升以及醫療保健基礎設施的改善。然而，亞太地區市場更加分散，國內外參與者眾多，由於成本敏感性，該地區越來越關注學名藥生產。另一方面，歐洲、中東和非洲是一個成熟的市場，具有嚴格的監管標準，並且注重藥物的功效和安全性。歐洲藥品管理局 (EMA) 下的統一歐盟 (EU)法規結構有助於簡化成員國之間的醫藥品認證過程，但也為新參與企業設置了嚴格的市場進入障礙。儘管 EMEA 中東和非洲市場規模較小，但由於醫療基礎設施投資增加以及對慢性病管理的興趣日益濃厚，該市場正在逐漸擴大。

FPNV定位矩陣

FPNV定位矩陣對於評估動脈粥狀硬化藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對動脈粥狀硬化藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

該報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.動脈硬化治療藥物市場規模及預測為何？

2.動脈粥狀硬化藥物市場預測期間需要考慮投資的產品、細分市場、應用和領域有哪些？

3.動脈硬化治療藥物市場的技術趨勢和法規結構是什麼？

4.動脈粥狀硬化治療藥物市場主要廠商的市場佔有率為何？

5.進入動脈粥狀硬化藥物市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 心血管疾病和動脈粥狀硬化疾病的盛行率增加
      • 努力促進心臟病的診斷和早期治療
    • 抑制因素
      • 動脈硬化治療藥物回想風險
    • 機會
      • 正在進行的研究計劃引進先進的動脈粥狀硬化藥物
      • 政府對動脈粥狀硬化藥物的核准增加
    • 任務
      • 動脈硬化開發新藥的併發症
  • 市場區隔分析
    • 藥物類別： 降膽固醇藥物治療普通動脈硬化採用率高
    • 交付管道：透過線上管道提高動脈粥狀硬化藥物的可得性
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章依藥物類別分類的動脈硬化治療藥物市場

  • 抗高血壓藥
  • 抗血小板藥
  • 降低膽固醇藥物

第7章動脈硬化治療藥物市場：依給藥途徑

  • 可注射的
  • 口服

第8章依疾病階段分類的動脈硬化治療藥物市場

  • 動脈粥狀硬化
  • 動脈粥狀硬化斑塊的形成
  • 脂肪紋的形成

第9章動脈硬化治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章 北美和南美動脈粥狀硬化治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區動脈硬化藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲動脈粥狀硬化治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 美國國立衛生研究院 (NIH) 向德克薩斯心臟研究所撥款 114 萬美元，用於開發新藥
    • 美國FDA核准諾華 Rekvio (inclisiran) 的適應症擴大至高 LDL 膽固醇水平的成人
    • FDA核准心血管疾病的發炎藥
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-F97DD5A7DBFE

[188 Pages Report] The Atherosclerosis Drugs Market size was estimated at USD 22.59 billion in 2023 and expected to reach USD 23.82 billion in 2024, at a CAGR 5.66% to reach USD 33.23 billion by 2030.

Atherosclerosis drugs refer to a variety of medications designed to slow or reverse the buildup of plaque in the arteries, a condition known as atherosclerosis. This buildup can lead to heart disease, stroke, and other cardiovascular issues. The major factors contributing to the expansion of their use include the rising prevalence of cardiovascular diseases globally, increased awareness and diagnosis rates, advancements in drug development, and a growing aging population at higher risk of developing atherosclerosis. However, these drugs are not without their challenges, such as potential side effects, varying efficacy among individuals, and the high cost of treatment, particularly with newer, patent-protected medications. Addressing these issues requires ongoing research to develop more effective and safer medications, implement strategies to reduce healthcare costs, and improve patient education on lifestyle changes that can complement drug therapy. Biotechnology advancements and personalized medicine approach that tailor treatment to the individual's genetic makeup is expected to diversify the opportunities for the improved development of atherosclerosis drugs.

KEY MARKET STATISTICS
Base Year [2023] USD 22.59 billion
Estimated Year [2024] USD 23.82 billion
Forecast Year [2030] USD 33.23 billion
CAGR (%) 5.66%

Drug Class: High adoption of cholesterol-lowering drugs for general atherosclerosis treatment

Antiplatelet agents are drugs that prevent blood platelets from clumping together to form clots. Clot formation is a major contributing factor in the narrowing of arteries in atherosclerosis, which can lead to heart attacks and strokes. By inhibiting platelet aggregation, these drugs reduce the risk of such events. Anti-hypertensive drugs are medications used to lower blood pressure in individuals with hypertension. High blood pressure is a significant risk factor for the development of atherosclerosis and its complications. These drugs work through various mechanisms to reduce blood pressure, reducing the cardiovascular system's strain. Cholesterol-lowering drugs, also known as lipid-lowering medications, primarily reduce levels of lipids (fats) in the blood, particularly low-density lipoprotein (LDL) cholesterol, which is a major component of arterial plaque. Lowering LDL cholesterol reduces the progression of atherosclerosis and the risk of cardiovascular events.

Distribution Channel: Improved availability of atherosclerosis drugs through online channels

Hospital pharmacies represent a primary distribution channel, particularly for acute treatment and management of atherosclerosis within a clinical setting. This channel ensures immediate access to necessary medications for patients under hospital care, facilitating prompt treatment initiation. Retail pharmacies serve as a critical channel for the distribution of atherosclerosis drugs directly to the public. They offer extensive geographical coverage, providing accessible medication dispensation to a broad patient demographic, including both urban and rural areas. Retail pharmacies enable patients to fill prescriptions through a physical storefront, which can be pivotal in managing chronic conditions, including atherosclerosis, outside of a hospital setting. Online pharmacies have emerged as a rapidly growing distribution channel owing to advances in digital health platforms. They offer a convenient option for patients to order their drugs online and have them delivered directly to their doorstep. This channel is particularly advantageous for individuals with mobility issues or those residing in remote areas.

Regional Insights

The Americas showcases significant atherosclerosis drug development, backed by robust R&D infrastructure, significant healthcare expenditure, and a strong presence of leading pharmaceutical companies. This region benefits from advanced healthcare frameworks and favorable government policies promoting drug innovation and quick adoption. Conversely, the APAC region, led by countries such as China, Japan, and India, is experiencing rapid growth in the atherosclerosis drugs market. This surge is powered by increasing healthcare awareness, rising cardiovascular disease prevalence, and improving healthcare infrastructures. However, APAC's market is more fragmented with a mix of local and international players, and there is a rising focus on generic drug production due to cost sensitivity in the region. On the other hand, EMEA presents a mature market scenario with stringent regulatory standards and a strong emphasis on drug efficacy and safety. The European Union's unified regulatory framework under the European Medicines Agency (EMA) facilitates a streamlined process for drug approval across member states yet poses challenging market entry barriers for new players. The Middle East and Africa segment of EMEA, while smaller in market size, is gradually expanding, owing to increasing investment in healthcare infrastructure and a growing focus on chronic disease management.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Atherosclerosis Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Atherosclerosis Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Atherosclerosis Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agepha Pharma US, Amgen Inc., Anthos Therapeutics, Artery Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Cardurion Pharmaceuticals, CSL Behring, Eli Lilly and Company, Esperion Therapeutics, Inc., NewAmsterdam Pharma, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, and Verve Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Atherosclerosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Class
    • Anti-Hypertensive Drugs
    • Antiplatelet Agents
    • Cholesterol-lowering Drugs
  • Route of Administration
    • Injectable
    • Oral
  • Disease Stage
    • Atheroma Formation
    • Atherosclerotic Plaques Formation
    • Fatty Streaks Formation
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Atherosclerosis Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Atherosclerosis Drugs Market?

3. What are the technology trends and regulatory frameworks in the Atherosclerosis Drugs Market?

4. What is the market share of the leading vendors in the Atherosclerosis Drugs Market?

5. Which modes and strategic moves are suitable for entering the Atherosclerosis Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of CVDs and atherosclerosis diseases
      • 5.1.1.2. Initiatives promoting diagnosis and early treatment of heart diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Risk of recalls of atherosclerosis drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research projects for introducing advanced atherosclerosis drugs
      • 5.1.3.2. Rising government approvals for atherosclerosis drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complications of new atherosclerosis drug development
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: High adoption of cholesterol-lowering drugs for general atherosclerosis treatment
    • 5.2.2. Distribution Channel: Improved availability of atherosclerosis drugs through online channels
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Atherosclerosis Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-Hypertensive Drugs
  • 6.3. Antiplatelet Agents
  • 6.4. Cholesterol-lowering Drugs

7. Atherosclerosis Drugs Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injectable
  • 7.3. Oral

8. Atherosclerosis Drugs Market, by Disease Stage

  • 8.1. Introduction
  • 8.2. Atheroma Formation
  • 8.3. Atherosclerotic Plaques Formation
  • 8.4. Fatty Streaks Formation

9. Atherosclerosis Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Americas Atherosclerosis Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Atherosclerosis Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Atherosclerosis Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. NIH Awards The Texas Heart Institute USD 1.14 Million To Develop A Novel Drug For Atherosclerotic Cardiovascular Disease
    • 13.3.2. US FDA Approves Expanded Indication For Novartis Leqvio (inclisiran) For Adults With High LDL-C
    • 13.3.3. Anti-Inflammatory Drug for Cardiovascular Disease Approved by FDA
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ATHEROSCLEROSIS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ATHEROSCLEROSIS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ATHEROSCLEROSIS DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. ATHEROSCLEROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. ATHEROSCLEROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ATHEROSCLEROSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVE DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ANTI-HYPERTENSIVE DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ANTIPLATELET AGENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATHEROMA FORMATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATHEROMA FORMATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATHEROSCLEROTIC PLAQUES FORMATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATHEROSCLEROTIC PLAQUES FORMATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FATTY STREAKS FORMATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FATTY STREAKS FORMATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 55. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 56. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 63. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 64. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 71. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 72. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 79. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 80. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 100. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 107. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 108. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 115. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 116. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 123. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 124. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 131. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 132. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 139. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 140. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 148. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 155. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 156. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 164. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 171. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 172. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 179. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 180. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 187. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 188. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 205. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 206. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 213. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 214. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 221. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 222. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 229. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 230. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 237. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 238. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 245. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 246. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 253. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 254. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 262. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 269. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 270. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 277. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 278. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 285. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 286. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 293. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 294. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 301. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 302. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 303. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 304. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 310. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 312. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 318. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 320. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISEASE STAGE, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 325. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2023 (USD MILLION)
  • TABLE 326. SPAIN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024-2030 (USD MIL